Summary of share price highs, lows and changes for Merck
Historical stock prices
Current Share Price	US$81.02
52 Week High	US$119.38
52 Week Low	US$73.31
Beta	0.38
1 Month Change	-3.79%
3 Month Change	3.50%
1 Year Change	-31.32%
3 Year Change	-6.49%
5 Year Change	-2.54%
Change since IPO	7,101.78%

Recent updates

Merck: Buy The Weakness

Aug 16

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Aug 12

Merck & Co., Inc.'s (NYSE:MRK) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 20

Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

Merck & Co.: Pipeline Resilience To Unlock Value

Apr 21

Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook

Mar 26

Merck & Co.'s Real Value: A Deep Dive Into Its Fundamentals

Feb 26

The Merck & Co., Inc. (NYSE:MRK) Annual Results Are Out And Analysts Have Published New Forecasts

Feb 06

Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)

Feb 04

High-Quality Dividend Growth Stocks Near 52-Week Lows: Merck Is Magnificent

Jan 20

Merck: A Low-Hanging Fruit To Pick

Dec 23

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Dec 20

Merck: Buy Opportunity Backed By Growth

Dec 17

Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.81

Dec 02

Shareholder Returns

	MRK	US Pharmaceuticals	US Market
7D	-3.7%	-0.6%	1.9%
1Y	-31.3%	-13.3%	18.9%

Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned -13.3% over the past year.

Return vs Market: MRK underperformed the US Market which returned 18.9% over the past year.

Price Volatility

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	3.5%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	17.5%
10% least volatile stocks in US Market	3.0%

Stable Share Price: MRK has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1891	74,000	Rob Davis	www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
MRK fundamental statistics
Market cap	US$206.84b
Earnings (TTM)	US$16.41b
Revenue (TTM)	US$63.62b

12.3x

P/E Ratio

3.2x

P/S Ratio

Is MRK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRK income statement (TTM)
Revenue	US$63.62b
Cost of Revenue	US$14.37b
Gross Profit	US$49.25b
Other Expenses	US$32.84b
Earnings	US$16.41b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 30, 2025

Earnings per share (EPS)	6.57
Gross Margin	77.41%
Net Profit Margin	25.79%
Debt/Equity Ratio	72.2%

How did MRK perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

49%

Payout Ratio

Does MRK pay a reliable dividends?

See MRK dividend history and benchmarks

When do you need to buy MRK by to receive an upcoming dividend?
Merck dividend dates
Ex Dividend Date	Sep 15 2025
Dividend Pay Date	Oct 07 2025
Days until Ex dividend	2 days
Days until Dividend pay date	20 days

Does MRK pay a reliable dividends?

See MRK dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/15 11:56
End of Day Share Price	2025/09/15 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merck & Co., Inc. is covered by 58 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Fabrizio Spagna	Axia Financial Research
Charles Butler	Barclays

Merck (MRK) Stock Overview

Rewards

Risk Analysis

US Investments And New Product Launches Will Shape Future Markets

Aging Populations And Biotech Breakthroughs Will Drive Expansion

Global Pricing Pressures Will Erode Margins Amid Rising Regulatory Scrutiny

Acqusition and awaiting analysis

Merck & Co., Inc. Competitors

Johnson & Johnson

Bristol-Myers Squibb

Pfizer

Zoetis

Price History & Performance

Recent News & Updates

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Upcoming dividend of US$0.81 per share

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Recent updates

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Upcoming dividend of US$0.81 per share

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Merck: Buy The Weakness

Health Canada Approves KEYTRUDA for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours That Are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined with Radiotherapy with or Without Cisplatin Then as Monotherapy

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Merck Announces Positive Topline Results from the Phase 3 KEYTRUDA Trial in Patients with Muscle-Invasive Bladder Cancer

Second quarter 2025 earnings: EPS misses analyst expectations

Merck & Co., Inc. Updates Sales Guidance for the Year 2025

First quarter dividend of US$0.81 announced

Merck Declares Fourth-Quarter 2025 Dividend, Payable on October 7, 2025

Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

FDA Grants Priority Review for WinrevaIR (sotatercept-csrk) to Update Label Based on Results from Zenith Trial of Merck & Co., Inc

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 1000 Dynamic Index

Acip Recommends Use of Merck's Enflonsia for Prevention of Respiratory Syncytial Virus

Merck Announces Phase 3 HYPERION Study of Winrevair Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)

Merck Manuals Launches AI-Powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

FDA Approves Merck's Anti-PD-1 Therapy

Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

Merck Announces Positive Topline Results from the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults with Hyperlipidemia

Merck Reportedly Held Talks to Buy MoonLake for over $3B

First quarter dividend of US$0.81 announced

Merck's Investigational Zilovertamab Vedotin at 1.75 mg/Kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients with Relapsed/Refractory DLBCL in Phase 2 Portion of Waveline-003 Trial

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025

Merck & Co., Inc.'s (NYSE:MRK) CEO Will Probably Find It Hard To See A Huge Raise This Year

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival in Patients with Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers

Research on Novel Treatment Approaches and Scientific Advances from Merck's Broad and Differentiated Oncology Portfolio and Pipeline to Be Presented at ASCO 2025

Dawn Health and Merck Launch Next-Generation Digital Ecosystem for Growth Disorders

New minor risk - Insider selling

Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Merck Announces Results from the Phase 3 KEYNOTE-689 Trial Evaluating KEYTRUDA

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Merck & Co.: Pipeline Resilience To Unlock Value

Merck & Co., Inc., Annual General Meeting, May 27, 2025

Merck Announces First Presentation of Results from the Phase 3 Zenith Trial Evaluating Winrevair™

Merck & Co., Inc.'s Investigational Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Demonstrates Noninferior Pharmaceuticaletics Compared to Intravenous (IV) KEYTRUDA®? (Pembrolizumab) in Pivotal 3475A-D77 Trial

European Commission Approves Merck's Capvaxive®? (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook

Merck Data At Acc.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease

Merck Announces Positive Data from Phase 3 Trials That Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir Maintained HIV-1 Viral Suppression At Week 48

Upcoming dividend of US$0.81 per share

Insider recently sold US$715k worth of stock

Merck & Co.'s Real Value: A Deep Dive Into Its Fundamentals

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Merck Receives First European Commission Approval for Two Indications

Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer

Independent Director recently bought US$1.3m worth of stock

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

The Merck & Co., Inc. (NYSE:MRK) Annual Results Are Out And Analysts Have Published New Forecasts

Full year 2024 earnings: EPS misses analyst expectations